Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 80, No. 2, 2008
Issue release date: March 2008
Section title: Review
Free Access
Urol Int 2008;80:113–123

Mathematical Models for Prognostic Prediction in Patients with Renal Cell Carcinoma

Galfano A.a · Novara G.a · Iafrate M.a · Cavalleri S.a · Martignoni G.c · Gardiman M.b · D’Elia C.a · Patard J.J.d · Artibani W.a · Ficarra V.a
aDepartment of Oncological and Surgical Sciences, Urology Clinic and bDepartment of Pathology, University of Padua, Padua, and cDepartment of Pathology, University of Verona, Verona, Italy; dDepartment of Urology, University of Rennes, Rennes, France
email Corresponding Author

Vincenzo Ficarra, Assoc. Prof.

Department of Oncological and Surgical Sciences, Urology Clinic

University of Padua, Via Giustiniani, 2

IT–35100 Padova (Italy)

Tel. +39 049 821 2720, Fax +39 049 821 8757, E-Mail vincenzo.ficarra@unipd.it


  1. Patard JJ, Rioux-Leclercq N, Fergelot P: Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 2006;49:633–643.
  2. Lohse CM, Cheville JC: A review of prognostic pathologic features and algorithms for patients treated surgically for renal cell carcinoma. Clin Lab Med 2005;25:433–464.
  3. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, de la Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005;23:2763–2771.
  4. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA: Evaluating the yield of medical tests. JAMA 1982;247:2543–2546.
  5. Yaycioglu O, Roberts WW, Chan T, Epstein JI, Marshall FF, Kavoussi LR: Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 2001;58:141–145.
  6. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P: A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001;166:63–67.
  7. Zisman A, Pantuck AJ, Dorey F, Said JW, Shvarts O, Quintana D, Gitlitz BJ, deKernion JB, Figlin RA, Belldegrun AS: Improved prognostication of renal cell carcinoma using an Integrated Staging System. J Clin Oncol 2001;19:1649–1657.
  8. Zisman A, Pantuck AJ, Wieder J, Chao DH, Dorey F, Said JW, deKernion JB, Figlin RA, Belldegrun AS: Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002;20:4559–4566.
  9. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H: An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 2002;168:2395–2400.
  10. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20:289–296.
  11. Cindolo L, de la Taille A, Messina G, Romis L, Abbou CC, Altieri V, Rodriguez A, Patard JJ: A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 2003;92:901–905.
  12. Leibovich B, Blute ML, Cheville JC, Lohse CM, Frank I, Kwon ED, Weaver AL, Parker AS, Zincke H: Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma. Cancer 2003;97:1663–1671.
  13. Leibovich B, Han K, Bui MH, Pantuck AJ, Dorey FJ, Figlin RA, Belldegrun A: Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma. Cancer 2003;98:2566–2575.
  14. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, et al: Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004;10:5464–5471.
  15. Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA: Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005;173:1496–1501.
  16. Sorbellini M, Kattan MW, Snyder ME, Reuter V, Motzer R, Goetzl M, McKiernan J, Russo P: A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005;173:48–51.
  17. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, de la Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ: Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol 2007;25:1316–1322.
  18. Cindolo L, Patard JJ, Chiodini P, Schips L, Ficarra V, et al: Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 2005;104:1362–1371.
  19. Hupertan V, Roupret M, Poisson JF, Chretien Y, Dufour B, Thiounn N, Mejean A: Low predictive accuracy of the Kattan postoperative nomogram for renal cell carcinoma recurrence in a population of French patients. Cancer 2006;107:2604–2608.
  20. Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin RA, Mulders PF, Belldegrun AS: Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol 2003;170:2221–2224.
  21. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, de la Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS: Use of the University of California Los Angeles Integrated Staging System to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004;22:3316–3322.
  22. Ficarra V, Martignoni G, Lohse C, Novara G, Pea M, Cavalleri S, Artibani W: External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer-specific survival using a European series of conventional renal cell carcinoma. J Urol 2006;175:1235–1239.
  23. Thompson RH, Leibovich BC, Lohse CM, Cheville JC, Zincke H, Blute ML, Frank I: Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score. J Urol 2007;177:477–480.
  24. Mekhail TM, Abou-Jawde RM, Boumerhi G, Malhi S, Wood L, Elson P, Bukowski R: Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005;23:832–841.
  25. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P: Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 2006;24:3101–3106.
  26. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML: Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 2003;27:612–624.
  27. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Storkel S, van den Berg E, Zbar B: The Heidelberg classification of renal cell tumours. J Pathol 1997;183:131–133.
  28. Ficarra V, Martignoni G, Galfano A, Novara G, Gobbo S, Brunelli M, Pea M, Zattoni F, Artibani W: Prognostic role of the histologic subtypes of renal cell carcinoma after slide revision. Eur Urol 2006;50:786–793.
  29. Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ: Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 2000;89:604–614.
  30. Sengupta S, Lohse CM, Leibovich BC, Frank I, Thompson RH, Webster WS, Zincke H, Blute ML, Cheville JC, Kwon ED: Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005;104:511–520.
  31. Sika-Paotonu D, Bethwaite PB, McCredie MR, William Jordan T, Delahunt B: Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. Am J Surg Pathol 2006;30:1091–1096.
  32. Sobin LH, Wittekind C: TNM Classification of Malignant Tumours. Introduction. New York, Wiley-Liss, 2002.
  33. Ficarra V, Guille F, Schips L, de la Taille A, Prayer Galetti T, Tostain J, Cindolo L, Novara G, Zigeuner R, Bratti E, Li G, Altieri V, Abbou CC, Zanolla L, Artibani W, Patard JJ: Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer 2005;104:2116–2123.
  34. Thompson RH, Cheville JC, Lohse CM, Webster WS, Zincke H, Kwon ED, Frank I, Blute ML, Leibovich BC: Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy. Cancer 2005;104:53–60.
  35. Ficarra V, Novara G, Iafrate M, Cappellaro L, Bratti E, Zattoni F, Artibani W: Proposal for reclassification of the TNM staging system in patients with locally advanced (pT3–4) renal cell carcinoma according to the cancer-related outcome. Eur Urol 2007;51:722–731.
  36. Terrone C, Cracco C, Porpiglia F, Bollito E, Scoffone C, Poggio M, Berruti A, Ragni F, Cossu M, Scarpa RM, Rossetti SR: Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 2006;49:324–331.